| Risk | Moderately High |
|---|---|
| Min SIP Amount | Not Supported |
| Expense Ratio | 0.00% |
| NAV | ₹8.91 (19 Oct 2020) |
|---|---|
| Fund Started | 27 Mar 2018 |
| Fund Size | ₹236 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| PI Industries Ltd. | Chemicals | Equity | 6.9% |
| Escorts Ltd. | Automobile | Equity | 6.3% |
| Coromandel International Ltd. | Chemicals | Equity | 5.8% |
| Bharti Airtel Ltd. | Communication | Equity | 5.7% |
| Mahindra & Mahindra Ltd. | Automobile | Equity | 5.7% |
| Colgate-Palmolive (India) Ltd. | FMCG | Equity | 5.5% |
| ITC Ltd. | FMCG | Equity | 5.1% |
| Bayer CropScience Ltd. | Healthcare | Equity | 4.7% |
| Chambal Fertilisers & Chemicals Ltd. | Chemicals | Equity | 4.3% |
| Rallis India Ltd. | Chemicals | Equity | 4.2% |
UTI Long Term Advantage Fund Series VII Direct Growth is a Equity Mutual Fund Scheme launched by Axis Mutual Fund. This scheme was made available to investors on 27 Mar 2018. Lalit Nambiar is the Current Fund Manager of UTI Long Term Advantage Fund Series VII Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹236 Cr and the Latest NAV as of 19 Oct 2020 is ₹8.91.
The UTI Long Term Advantage Fund Series VII Direct Growth is rated Moderately High risk.
The investment objective of the scheme is to provide medium to long term capital appreciation along with income tax benefit.